Taiwan is making great strides in developing its biotech sector, but reaching the NT$ trillion mark in annual production value by 2025 won’t be easy. When the Biotech Innovation Organization (BIO), the world’s leading industry association for biotechnology, chose to hold its annual regional conference this summer in Taipei, it was a big boost for…
In the fast-growing, relatively new field of biopharmaceuticals, California-based Amgen has been one of the standout performers. Founded in 1980, it earned a record US$23.7 billion in revenue last year to rank in 123rd place on the Fortune 500 list of the largest U.S. corporations. It also ranked within the world’s top 10 drug companies…
When the Taiwan government last year unveiled its 5+2 Innovative Industries plan with biomedicine as one of the cornerstones, the multinational pharmaceutical industry noted that development with keen interest and optimism. Taiwan can point to numerous assets that could make it a serious contender to become a regional or even global hub for biopharma. It…
Transforming Taiwan into a regional biomedical hub will require some creativity. Taiwan’s biomedicine industry has many of the ingredients for success. The island has strong scientific talent, rich clinical-trial experience, abundant capital, a treasure trove of medical data (from the National Health Insurance system), information-technology expertise, and strong intellectual property rights protection bolstered by the…
Finding new treatments for difficult to cure diseases Devoted to improving local education and medical care Although Chicago-based AbbVie was founded only five years ago, its performance in delivering new drugs for hard-to-treat diseases and its dedication to improving local medical services and education have quickly received global attention. “Our goal is to provide groundbreaking…
Development of the biotech, biopharmaceutical, and medical device industries offers an opportunity not only to advance Taiwan’s technology and grow its economy, but also provide solutions to many of the problems faced by an aging society. “Taiwan is aging at a rapid rate and we need new ideas and new approaches by industry to tackle…
Taiwan is banking hard on biopharma, and investments that were made in previous decades are now close to bearing fruit. Flush with cash and success, some of Taiwan’s most renowned biopharma firms are on the cusp of bringing to market first-in-class, breakthrough drugs targeting some of humanity’s worst scourges, such as AIDS, cancer, and hepatitis….
